Vertex Pharmaceuticals (VRTX) Q2 2026 Earnings
How Did VRTX Stock React to Q2 2026 Earnings?
S&P 500 over the same 30 days: +0.24%.
Did VRTX Beat Earnings? Q2 2026 Results
No. Vertex Pharmaceuticals reported Q2 2026 earnings of $4.73 a share on Aug 3, 2026, missing the $4.75 consensus estimate by 0.3%. Revenue was $3.3B against a $3.2B estimate.
Vertex Pharmaceuticals delivered a mixed but broadly strong second quarter for fiscal 2026, with revenue clearing Wall Street's bar even as earnings came in just shy of expectations, <a href="https://247wallst.com/investing/2026/08/03/live-will-tonights-q2-earnings-report-send-vertex-pharmaceuticals-higher/">a result investors had been watching closely</a> after shares fell roughly 10% in the weeks leading up to the report. Total revenue rose 12.4% year-over-year to $3.33 billion, beating the $3.22 billion consensus by 3.43%, while adjusted EPS of $4.73 missed the $4.75 estimate by a narrow 0.32%. The headline growth was anchored by the cystic fibrosis franchise, where TRIKAFTA/KAFTRIO contributed $2.50 billion and the newer ALYFTREK added $573.60 million as global reimbursement expanded to 25 countries. Non-CF products are increasingly in the mix as well, with CASGEVY revenue up 151% year-over-year to $76.40 million and JOURNAVX reaching $49.60 million after more than quadrupling from a year ago. Management raised full-year 2026 revenue guidance to $13.10 billion to $13.20 billion, citing CF momentum and at least $500 million in non-CF product revenue, while the pending $10 billion acquisition of Crinetics Pharmaceuticals was not incorporated into the updated outlook.
- Continued strong CF patient demand and new ALYFTREK initiations
- Higher realized net CF prices versus prior year
- CASGEVY revenue growth of 151% YoY and 78% quarter-over-quarter
- JOURNAVX revenue more than quadrupled YoY with approximately 535,000 Q2 prescriptions
- Favorable foreign exchange impact on ex-U.S. revenue
- ALYFTREK reimbursement expansion to 25 countries
“Vertex delivered excellent second quarter results, expanding our leadership in cystic fibrosis; delivering strong revenue growth in sickle cell disease, beta thalassemia, and acute pain; and with the pending acquisition of Crinetics, adding rare endocrine diseases as our fifth pillar, further diversifying our portfolio.”
Vertex Pharmaceuticals CEO, on the earnings call
What Is Vertex Pharmaceuticals's Outlook?
Vertex raised its full-year 2026 total revenue guidance to $13.1 billion to $13.2 billion from $12.95 billion to $13.1 billion previously. The guidance embeds expectations for continued CF growth including global ALYFTREK and TRIKAFTA uptake, and $500 million or more in revenue from non-CF products (CASGEVY and JOURNAVX). Revenue guidance reflects an approximately 150 basis point year-over-year benefit from foreign exchange. Combined GAAP R&D, AIPR&D and SG&A expense guidance is unchanged at $6.3 billion to $6.45 billion, and non-GAAP at $5.65 billion to $5.75 billion. Tariff cost impact is expected to be immaterial in 2026. This guidance does not reflect the pending Crinetics acquisition, which is expected to close in Q3 2026; updated guidance will be provided following transaction close.
VRTX YoY Financials
| Metric | Q2 2026 | Q2 2025 | Year over year |
|---|---|---|---|
| Revenue | $3.3B | $3.0B | +12.5% |
| Gross Profit | $2.8B | $2.6B | +11.2% |
| Operating Income | $1.2B | $1.2B | +8.3% |
| Net Income | $1.1B | $1.0B | +6.5% |
VRTX Revenue by Segment
VRTX Revenue by Geography
When Does Vertex Pharmaceuticals Report Next?
Figures from SEC filings and company reports. Not investment advice.